All the below link and tweets are in English.
Vol.122 (New Jersey ニュージャージー州 Vol.3: pharmaceutical corporations 製薬会社）の続き
ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
Japan's PeptiDream to work with Merck in developing COVID-19 therapies https://t.co/GzIqX0LbZQ pic.twitter.com/T8MxO4ZuZu
— Reuters (@Reuters) June 12, 2020
CDC Director Brenda Fitzgerald bought stock in Japan Tobacco, Merck and Humana– *AFTER* she became the nation's top public health official.
The investigation from @SarahKarlin
& @Briannaehley: https://t.co/gHNHqOP8IG— Adam Cancryn (@adamcancryn) January 30, 2018
During COVID, the growing dangers and threat posed by antibiotic-resistant bacteria outweigh the global level of preparedness. Meanwhile, antibiotic R&D is suffering for investment. Forge applauds @Merck and Kyorin for supporting @PewCharitableTrust https://t.co/i0ToNjccgt
— Forge Therapeutics (@ForgeThera) October 23, 2020
New data from Merck, Kyorin shared to Pew's SPARK @pewtrusts @Merckhttps://t.co/ibg9R6JXFn
— The Science Advisory Board (@ScienceBoard) October 21, 2020
“Our hope is that the data from @Merck’s research will help catalyze discovery of new #antibiotics for Gram-negative pathogens,” @pewhealth’s @KathrynTalking says of the pharmaceutical company’s recent data contribution to SPARK. https://t.co/qd6oOf3y15
— Save Antibiotics (@saveantibiotics) October 21, 2020
Japan Prize / Merck-Banyu Lectureship for Naoya Kumagai / DECHEMA Prize for Timothy Noeel (News) https://t.co/npKfaLlQBg pic.twitter.com/6Q1xQyXK11
— Angewandte Chemie (@angew_chem) April 26, 2018
In today's News Briefing: Two years unveiling a flop in their first PhIII trial of guadecitabine as a frontline treatment, Otsuka is back with 2 more pivotal setbacks. And the #FDA approved an expanded indication for Merck’s best-seller Keytruda. https://t.co/5svHdzG7UG
— Endpoints News (@endpts) October 16, 2020
Merck adds to lung cancer wall with Otsuka deal https://t.co/l9RW0Njibg pic.twitter.com/GnYs2TWMeI
— HealthIT and Biotech (@UCCharting) January 9, 2020
Merck adds to lung cancer wall with Otsuka deal | BioPharma Dive https://t.co/k063lZ3W8E
— Mr. Brian Uberig (@Brian_Uberig) January 8, 2020
MSD enlists Otsuka units Taiho and Astex to develop KRAS therapies https://t.co/2QOB4obxMj #pharma #healthcare
— PharmaTimes (@PharmaTimes) January 8, 2020
Merck and Otsuka enter into a research and development pact for a drug that targets a dangerous subset of cancers https://t.co/8ESVh069oT
— Bloomberg (@business) January 7, 2020
Merck & Co. partners with Otsuka units Taiho, Astex on cancer drug development https://t.co/qu7yCDMN5P $MRK $ASTX
— FirstWord Pharma (@fwpharma) January 6, 2020
Industry Insight of Oncolytic Virus Market Research Segment, In-depth Analysis | Merck, Otsuka Pharmaceutical Co, Pfizerhttps://t.co/lnfmzWgTWA#news #pharma #pharmiweb
— Pharma News (@pharminews) December 24, 2019
Oncolytic Virus Market Analysis and Reviews 2019 to 2025 | Merck, Otsuka Pharmaceutical Co, Pfizer, Roche, Cold Genesys, Genelux https://t.co/5MnJLhS6t2 pic.twitter.com/4THnWUqxql
— Science Examiner (@ScienceExaminer) October 7, 2019
Analyst Keshalini Sabaratnam @Pharma_GD on the #sales #forecast for @Merck and #Otsuka 's #Keytruda (pembrolizumab) projected to be top drug by 2023 and what does this mean for their #contractmanufacturers #CDMO #CMO @AstraZeneca @BoehringerDE https://t.co/R6Wmwcm2Qb
— GlobalData PharmSource (@PharmSource) October 2, 2019
The $200 discount for the Marketing Disruption Summit ends Friday! Explore the full agenda and get your tickets here: https://t.co/sueo5mBZEd#sanofi #BMS #ferring #boehringeringelheim #merck #teva #gsk #abbvie #astrazeneca #pfizer #bayer #otsuka #us #pharma #marketing #data #it pic.twitter.com/u9P8j4mLcn
— Reuters Events Pharma (@RE_Pharma) August 14, 2019
Otsuka buying Waltham, Mass.-based antibody specialist Visterra for $430 million, all-cash. https://t.co/FIwi2S4VeB
Last valuation was $188 million, per Pitchbook. Omega, Alexandria, Cycad Group, Gates Foundation, Merck, Vertex, Temasek, Alexandria among investors.
— Matthew Herper (@matthewherper) July 11, 2018
"Editor’s note: The author did not initially disclose having received payments from Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Lundbeck, Merck, Sharpe, and Dohme, Otsuka, Pfizer, and other companies." You have to ask – why the delay? @AmerGeriatrics https://t.co/RWpZYRJ7zK
— James Richardson, MD, MPH (@DocRock54) March 10, 2018
Merck and Otsuka US agree: Misalignment in healthcare is our biggest cha… https://t.co/H2U3iCqVZ1 via @YouTube
— Tim Nolan (@TimNolan1941) August 17, 2017
ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show https://t.co/mjqD8dcsru
— cafepharma (@cafepharma) September 20, 2020
Chasing Merck, Eisai launches insomnia drug Dayvigo in Japan https://t.co/e3JM6pAqPX
— cafepharma (@cafepharma) July 7, 2020
https://twitter.com/LRamseu/status/1312391912956010498
Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light #livercancernews https://t.co/uJyJ0rpuoG
— Blue Faery (@BlueFaeryLiver) September 16, 2020
US rejects MSD/Eisai's Keytruda Lenvima combo https://t.co/U6bwJRTYcK #lifesciences #news
— PharmaTimes (@PharmaTimes) July 9, 2020
Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light https://t.co/fCgfHt2mPc
— FiercePharma (@FiercePharma) July 8, 2020
Merck, Eisai to put experimental cancer combination in new clinical trial https://t.co/LuQoPj699g
— MarketWatch (@MarketWatch) July 8, 2020
Merck, Eisai to put experimental cancer combination in new clinical trial https://t.co/uoyKGe8up0
— MMC Anchor (@MMCAnchor) July 8, 2020
ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data https://t.co/f6piWgmPOf
— EIPG (@EIPGeu) June 1, 2020
.@Merck/@Eisai's Keytruda/Lenvima combo 1st to win simultaneous approvals from @US_FDA, @GovCanHealth & @TGAgovau under new international regulatory program for #cancer drugs, writes @biotechvisigoth. $MRK #oncology https://t.co/nAfqQ8mUqL
— MedCity News (@medcitynews) September 18, 2019
New #paediatric treatments recently launched for #HIV #soiltransmittedhelminths #epilepsy and #pneumonia from 4 companies detailed in #atmi2018 today: @GSK @JNJNews @Merck @eisai …. #worldChildrensDay2018 #WorldChildrensDay https://t.co/qnb3DoC0m1
— Danny Edwards (@dannyjedwards) November 20, 2018
#Eisai, #MSD start marketing activity for #LENVIMA https://t.co/qGiJ2CwZx0 via @AsiaBioSpectrum
— Sudam Walekar (@sudam_walekar) October 23, 2018
Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan https://t.co/oLX4MT3Vnu
— EIN Presswire: Merck Newswire (@EINMerckNews) October 22, 2018
Eisai/MSD’s Lenvima approved in Europe for liver cancer https://t.co/pPxoYTKCzG pic.twitter.com/Itatzdg438
— PIR International (@PIR_Intl) August 28, 2018
Merck, Eisai win FDA approval for Lenvima to treat unresectable HCC https://t.co/5tlVxTAiLO
— NGT Consulting (@NextGeneTherapy) August 20, 2018
Eisai and MSD team up to combine Lenvima and Keytruda in cancer https://t.co/K7XtG4RWnv pic.twitter.com/R9fukbkYeX
— Pharmamarketeer (@Pharmamarketeer) March 13, 2018
Merck partners with Eisai's Tyrosine Kinase inhibitor drug Lenvatinib with apotential deal of over 5 billion dollars#merck #Eisai #Checkpointinhibitor #Tyrosinerkinaseinhibitor #combination #billiondollar #deal #treat #malignancieshttps://t.co/NXsLRtc17N
— Neil Sankar (@SankarNeil) March 12, 2018
Merck and Eisai Ink $5.76B Cancer Deal https://t.co/bKH5FnuCC9 pic.twitter.com/RI1iJIIqLI
— Biotech World (@BiotechWorld) March 9, 2018
Eisai and MSD will jointly develop and commercialize a thyroid cancer therapy – https://t.co/Z1TfQSlksY pic.twitter.com/QVLB0ppzJT
— GMPnews.Net (@GMPnewsNet) March 8, 2018
Our final panel session at @PharEast2018 features Representatives from @JNJCares, Eisai Japan, MSD Singapore and Fosub-kite discussing on using real world evidence (RWD) to support the rational use of medicine in Asia. #phareast pic.twitter.com/LD4Y0kmqE4
— Phar-East (@PharEast2018) March 2, 2018
@gatesfoundation , @wellcometrust & @Mastercard Launch Initiative to Speed Development and Access to Therapies for COVID-19#COVID19TherapeuticsAccelerator #Covid19https://t.co/ATA8tRBLc7#BD #BI #Eisai #EliLilly #Gilead #GSK #JandJ #MSD #Merck #Novartis #Pfizer #Sanofi
— Claude Waddington (@Mr_C_Wadd) March 30, 2020
MSD and Eisai announce meaningful objective response rates for Keytruda+Lenvima combo in two cancer patient populations https://t.co/dRtWAbK5fk #pharma pic.twitter.com/2YDFuIMvrs
— Pharmafocus (@Pharmafocus) May 29, 2020
Eisai and MSD's Lenvima recommended for NHS Scotland in advanced or unresectable #LiverCancer https://t.co/bhdX1Yb5qR #cancer #pharma #NHS pic.twitter.com/H2qvj5SrrE
— Pharmafocus (@Pharmafocus) April 8, 2019
Thank you to our No One Fights Alone Virtual Gala Celebration sponsors, including Platinum Ribbon Sponsors, Amgen, Merck, Oncosec Immunotherapies, and Silver Ribbon Sponsors, Eisai and Immunomedics. Your generosity and support make it all possible. https://t.co/B8RsqHB5bW pic.twitter.com/KungeoGTTb
— TNBC Foundation (@TNBCFoundation) October 23, 2020
These pharma fleecers, including Takeda, Eisai, Merck, and Genentech, choose to sell their expensive oncology drugs in excessively large drug vials that lead to waste. They got my second #PharmaFleeceAward today.
— Senator Dick Durbin (@SenatorDurbin) March 14, 2019
Daiichi Sankyo signs clinical trial collaboration deal with Merck and Pfizer: Daiichi Sankyo has entered into a clinical trial collaboration agreement with Merck and Pfizer to evaluate the combination of its [fam-] trastuzumab deruxtecan (DS-8201) with… https://t.co/N83w7zGYxv
— cafepharma (@cafepharma) October 26, 2018
Daiichi-Merck partnership lines up Keytruda combo therapy https://t.co/YnoL7Sa9B6 pic.twitter.com/9Ocwq2ei5F
— JackLeckerman (@JackLeckerman) October 9, 2018
Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination therapy for breast or lung cancershttps://t.co/i08ieVPnZY pic.twitter.com/F3ZuKh8KUs
— Bio_Talent (@bio_talent) September 28, 2018
Unfortunately message is suspect bc of COI. F. Schiele reports personal fees from Board membership, consultancy, or lecturing from Sanofi, Amgen, Pfizer, AZ, MSD, BMS, Bayer & Daiichi-Sankyo. Steen Dalby Kristensen has recd lecture fees from AZ, Bayer, BMS/Pfizer and Boehringer- https://t.co/mKikYa72D9
— Ram Charan (@RamCharanji) January 11, 2018
Global Fibromyalgia Drugs market 2020: focuses on companies, opportunities, market size, growth, revenue & forecast 2026 | COVID19 Impact Analysis | Key Players: Pfizer, Eli Lilly, Actavis, Merck Sharp and Dohme, Daiichi Sankyo, etc. | InForGrowth – The … https://t.co/Z61iSQQlKs
— FMS News bot (@fmsbot) October 2, 2020
Hyperlipidemia Market: Market Data, Industry Analysis, Size,Share 2027 | Leading Players- AstraZeneca, Sanofi, Merck & Co., Pfizer, Daiichi Sankyo Company https://t.co/Wbz8agTS65
— Harshad Ramesh Borde (@BordeHarshad) August 25, 2020
The Next Boom Sector: Cancer
Physiomics #PYC is a leading oncology consultancy using its proprietary state of the art Virtual Tumour technology to predict and better understand effects of cancer treatments
Clients:
Merck, Astellas, Bicycle, Valirx, Cyclacel, CellCentric etc pic.twitter.com/djRsMNxJsc— Stockonomist (@Stockonomist) September 28, 2020
Thanks to our @ANZUPtrials #bestofGUoncology #ANZUPGU19 sponsors – @IpsenGroup Astellas Oncology @AstraZeneca @MSD_Aus pic.twitter.com/WtTfQE1djd
— ANZUP (@ANZUPtrials) November 6, 2019
.@NICEComms has been busy with announcements today, rejecting Astellas’ #Xospata for a certain type of acute myeloid leukaemia (AML) and querying evidence for MSD's #Keytruda in head and neck cancer https://t.co/vFcLhQXJnT
— pharmaphorum (@pharmaphorum) January 15, 2020
MSD acquires Takeda’s Dunboyne manufacturing facility https://t.co/zOsjPUDhHN
— Silicon Republic (@siliconrepublic) August 10, 2020
MSD buys Takeda biologics medicines plant in Dunboyne https://t.co/IflH6PU1MF via @IrishTimesBiz
— Irish Times Business (@IrishTimesBiz) August 7, 2020
MSD to takeover Takeda's Dunboyne facility https://t.co/ACUOaUBlOd
— RTÉ Business (@RTEbusiness) August 7, 2020
This is a very welcome announcement from MSD and Takeda. https://t.co/C6aqYapp57
— Martin D Shanahan (@MartinDShanahan) August 7, 2020
Takeda acquired Tim Clackson's prev company, ARIAD, in '17 for $5.2 Billion. He had originally joined ARIAD in 1994. In addition to Takeda & Merck/MRL, German Merck's M Ventures & Ipsen's venture fund are also corporate VCs that invested in the B round. They moved 2 Waltham, MA https://t.co/OxT4HM5RxL
— Pearl Freier (@PearlF) March 2, 2020
Takeda & Merck (MRL Ventures) r 2 of the investors in #CambMA-based immuno-oncology Xilio Therapeutics fka Akrevia. $100.5M B. Originally launched by @atlasventure & F-Prime. CEO is @OtherReneRusso & Tim Clackson is Prez & EVP R&D.MRL Ventures @dud3k BOD https://t.co/JaUnc6UUXD
— Pearl Freier (@PearlF) March 2, 2020
Takeda, Merck invest in cancer startup's Xilio Therapeutics $100M Series B round – Bizwomen https://t.co/GBIVu54ivm #venturecapital #earlystageinvestors #angelinvestors #startups
— Red Trait Ventures (@RedTrait) March 4, 2020
PharmaScrip: Executives On The Move: Exits From Takeda Vaccines And Novartis Institutes To CMO Positions And Board Changes At Merck & Co. https://t.co/1Ah2xcjDQI #PharmaScrip https://t.co/3BT9hqerzu pic.twitter.com/ON8dj4Klug
— ZorgNL (@zorgnl) February 13, 2020
Impact of COVID-19 on Colorectal Cancer Therapeutics Market Latest trending report is booming globally by Top Leading Players Taiho Pharma, Merck KGaA, Amgen, Takeda https://t.co/Xud5IlkmE0
— mednetnews (@mednetnews) October 17, 2020
Colorectal Cancer Therapeutics Market 2020-2026 | Comprehensive Study COVID19 Impact Analysis | Worldwide Key Players: Taiho Pharma, Merck KGaA, Amgen, Takeda, Roche, etc. https://t.co/rJMqyCbJPm
— mednetnews (@mednetnews) September 5, 2020
Global Innovative Drug Market Expected to Reach highest CAGR: Pfizer,Gilead Sciences,Johnson & Johnson,Roche,AbbVie,Sanofi,Amgen,Novartis,Merck & Co. (MSD),GlaxoSmithKline (GSK),Bayer,Takeda,AstraZeneca,Novo Nordisk https://t.co/An4NCt3fo9
— @ReportsandMarkets (@ReportsMarkets) October 13, 2020
#VaccinesEurope represents drugmakers including #AstraZeneca, #GlaxoSmithKline, #Janssen (which belongs to Johnson & Johnson), #Merck, #Novavax, #Pfizer, #Sanofi, #Takeda, #Abbott and #CureVac. Covid-19 vaccine makers #LobbyEU for #LegalProtection.https://t.co/FNImlmq8yE
— Riikka Kevo (@riikka_kevo) August 26, 2020
Lipid Metabolism Disease Drug Market Latest updates and Coronavirus (COVID-19) Impact on Global Market in 2020-2029 Merck, Takeda Pharmaceutical and Novartis – The Loop 21 https://t.co/xazRpkLaZ2
— Dr Jitesh Arora (@drjitesharora) July 29, 2020
Who would want a simple solution?
"thank the leadership of AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Eli Lilly, Evotec, Gilead, GlaxoSmithKline, Johnson & Johnson, KSQ Therapeutics, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vir"https://t.co/V20z6DAu2U
— sandeep chakraborty (@sanchak74) June 12, 2020
Global #pharmaceuticals unprecedented collaboration in the search for effective #COVID19 therapies. IFPMA press conference on 30 April 2020 with key speakers across MSD, Takeda, CSL, Pfizer, AstraZeneca, Sandoz and Merck.https://t.co/Blg8sI0uHX@IFPMA @ThomasCueni @MedicinesAus
— Rozalina Sarkezians (@RozalinaRS) May 1, 2020
Pray to Merck, Pfizer, Sanofi, Takeda, J&J, Lilly. Pray to all the start up biotechnology firms throughout the world. Pray to science. An imaginary friend in the sky will not help you. https://t.co/jGz1Ga4fID
— The Grackle ☠ (@LanceMa89524580) March 20, 2020
Takeda, Merck invest in Waltham cancer startup's $100M round https://t.co/KOtqmEQWpy
— Matthew Liptak (@mattliptak) March 2, 2020
Global Drugs for Lipid Metabolism Disease Market 2020 Raises During Pandemic Phase 2021 | Merck, Novartis, Takeda Pharmaceutical – Best News Monitoring https://t.co/6mUdaMY12P
— Dr Jitesh Arora (@drjitesharora) July 29, 2020
Skyhawk Therapeutics, one of GGC's first portfolio companies, recognized by BostInno as one of the 20 Boston Startups to Watch in 2020! Great progress on HUGE dollar contracts with Celgene / Bristol-Myers Squibb, Biogen, Merck, Takeda and Genentech. https://t.co/cktw5pUivN
— Good Growth Capital (@goodgrowthvc) December 23, 2019
